Difference between revisions of "Malignant solid neoplasm, EGFR-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
|||
Line 32: | Line 32: | ||
<div class="toccolours" style="background-color:#b3e2cd"> | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[Erlotinib (Tarceva)]] 150 mg PO once per day | + | *[[Erlotinib (Tarceva)]] 150 mg PO once per day on days 1 to 28 |
− | ''' | + | '''28-day cycles''' |
</div></div> | </div></div> | ||
===References=== | ===References=== |
Latest revision as of 00:59, 3 December 2023
1 regimens on this page
1 variants on this page
|
All lines of therapy
Erlotinib monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Hainsworth et al. 2018 (MyPathway) | 2014-2016 | Phase 2a, fewer than 20 pts in this arm |
Biomarker eligibility criteria
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141